These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 28410210)

  • 1. Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.
    Broos K; Keyaerts M; Lecocq Q; Renmans D; Nguyen T; Escors D; Liston A; Raes G; Breckpot K; Devoogdt N
    Oncotarget; 2017 Jun; 8(26):41932-41946. PubMed ID: 28410210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8
    Ertveldt T; Meulewaeter S; De Vlaeminck Y; Olarte O; Broos K; Van Calenbergh S; Bourgeois S; Deprez J; Heremans Y; Goyvaerts C; Staels W; De Smedt S; Dewitte H; Devoogdt N; Keyaerts M; Verbeke R; Barbé K; Lentacker I; Breckpot K
    Theranostics; 2023; 13(15):5483-5500. PubMed ID: 37908728
    [No Abstract]   [Full Text] [Related]  

  • 3. PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer.
    Heskamp S; Wierstra PJ; Molkenboer-Kuenen JDM; Sandker GW; Thordardottir S; Cany J; Olive D; Bussink J; Boerman OC; Dolstra H; Aarntzen EHJG; Hobo WA
    Cancer Immunol Res; 2019 Jan; 7(1):150-161. PubMed ID: 30459153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive Evaluation of Tumoral PD-L1 Using a Novel
    Hu B; Ma X; Shi L; Liu T; Li L; Yao M; Li C; Jia B
    Mol Pharm; 2024 Apr; 21(4):1977-1986. PubMed ID: 38395797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy.
    Gao H; Wu Y; Shi J; Zhang X; Liu T; Hu B; Jia B; Wan Y; Liu Z; Wang F
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive Imaging of Tumor PD-L1 Expression Using [
    Zhang Y; Ding Y; Li N; Wang S; Zhou S; Li R; Yang H; Li W; Qu J
    Mol Pharm; 2023 Jan; 20(1):690-700. PubMed ID: 36541699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.
    Chatterjee S; Lesniak WG; Gabrielson M; Lisok A; Wharram B; Sysa-Shah P; Azad BB; Pomper MG; Nimmagadda S
    Oncotarget; 2016 Mar; 7(9):10215-27. PubMed ID: 26848870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Phase I Study of a
    Xing Y; Chand G; Liu C; Cook GJR; O'Doherty J; Zhao L; Wong NCL; Meszaros LK; Ting HH; Zhao J
    J Nucl Med; 2019 Sep; 60(9):1213-1220. PubMed ID: 30796165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
    Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS
    J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.
    Lesniak WG; Chatterjee S; Gabrielson M; Lisok A; Wharram B; Pomper MG; Nimmagadda S
    Bioconjug Chem; 2016 Sep; 27(9):2103-10. PubMed ID: 27458027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.
    Natarajan A; Mayer AT; Reeves RE; Nagamine CM; Gambhir SS
    Mol Imaging Biol; 2017 Dec; 19(6):903-914. PubMed ID: 28247187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use.
    Lecocq Q; Zeven K; De Vlaeminck Y; Martens S; Massa S; Goyvaerts C; Raes G; Keyaerts M; Breckpot K; Devoogdt N
    Biomolecules; 2019 Sep; 9(10):. PubMed ID: 31569553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma.
    Nedrow JR; Josefsson A; Park S; Ranka S; Roy S; Sgouros G
    J Nucl Med; 2017 Oct; 58(10):1560-1566. PubMed ID: 28522738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immuno-SPECT/PET imaging with radioiodinated anti-PD-L1 antibody to evaluate PD-L1 expression in immune-competent murine models and PDX model of lung adenocarcinoma.
    Wen X; Shi C; Zhao L; Yao L; Xu D; Lin X; Su X; Liu T; Zhuang R; Lin Q; Chen H; Guo Z; Zhang X
    Nucl Med Biol; 2020; 86-87():44-51. PubMed ID: 32474281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody.
    Lv G; Sun X; Qiu L; Sun Y; Li K; Liu Q; Zhao Q; Qin S; Lin J
    J Nucl Med; 2020 Jan; 61(1):117-122. PubMed ID: 31253743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
    Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade.
    Ma L; Gai J; Qiao P; Li Y; Li X; Zhu M; Li G; Wan Y
    Biochem Biophys Res Commun; 2020 Oct; 531(2):144-151. PubMed ID: 32782142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FN3 linked nanobubbles as a targeted contrast agent for US imaging of cancer-associated human PD-L1.
    Kumar US; Natarajan A; Massoud TF; Paulmurugan R
    J Control Release; 2022 Jun; 346():317-327. PubMed ID: 35469983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Engineered Small Protein for Positron Emission Tomography Imaging of Human Programmed Death Ligand-1: Validation in Mouse Models and Human Cancer Tissues.
    Natarajan A; Patel CB; Ramakrishnan S; Panesar PS; Long SR; Gambhir SS
    Clin Cancer Res; 2019 Mar; 25(6):1774-1785. PubMed ID: 30373750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy.
    Chatterjee S; Lesniak WG; Nimmagadda S
    Mol Imaging; 2017; 16():1536012117718459. PubMed ID: 28707500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.